Skip to Content

Join the 'Alirocumab' group to help and get support from people like you.

Alirocumab News

Many Patients Denied Costly New Cholesterol Drugs

Posted 28 Sep 2017 by Drugs.com

THURSDAY, Sept. 28, 2017 – Expensive new medicines offer hope to patients with uncontrolled "bad" cholesterol, but the high cost keeps many patients from getting them, a new study says. The injectable drugs – approved for use in the United States in 2015 – are known as PCSK9 inhibitors. They include Praluent (alirocumab) and Repatha (evolocumab). But, researchers found, of tens of thousands of ...

New Cholesterol Drugs Vastly Overpriced, Study Contends

Posted 22 Aug 2017 by Drugs.com

TUESDAY, Aug. 22, 2017 – Are new medicines for people with out-of-control cholesterol wildly overpriced? It's a question that's sparking debate among consumers and providers of care. Now, researchers at the University of California, San Francisco (UCSF) report that the price of these drugs – called PCSK9 inhibitors – would have to be slashed by a whopping 71 percent to be deemed ...

Powerful New Cholesterol Med Won't Harm Memory, Easing Concerns

Posted 17 Aug 2017 by Drugs.com

WEDNESDAY, Aug. 16, 2017 – Despite some early concerns, a new study suggests the powerful cholesterol drugs known as PCSK9 inhibitors may not cause memory problems or other mental symptoms. The drugs, which include evolocumab (Repatha) and alirocumab (Praluent), were approved in the United States in 2015. That came after trials showed they can dramatically slash LDL cholesterol (the "bad" kind), ...

Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent (alirocumab) Injection

Posted 1 May 2017 by Drugs.com

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ – Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly (every four weeks), 300 mg dose of Praluent (alirocumab) Injection for the treatment of adults with high low-density ...

New Cholesterol Drugs May Beat Statins, But Price Tag Is High

Posted 17 Mar 2017 by Drugs.com

FRIDAY, March 17, 2017 – Two different injectable drugs can lower cholesterol levels even further than statins do, potentially warding off future heart attacks or strokes, new research suggests. However, some heart experts question whether the pricey medications, one of which costs roughly $14,000 a year to take, perform well enough to make them worth the extra money. In fact, some cardiologists ...

Study Suggests Newer Cholesterol Drugs Are Safe

Posted 31 Jan 2017 by Drugs.com

MONDAY, Jan. 30, 2017 – A combination of drugs that drastically lowers "bad" cholesterol levels appears safe for heart patients, but whether it prevents heart attacks or strokes isn't yet known, researchers report. "It may be that people need very low cholesterol levels to get a benefit in terms of heart attacks and stroke reduction, but that remains to be determined," said lead researcher Dr. ...

Are There Alternatives to Statins?

Posted 27 Sep 2016 by Drugs.com

TUESDAY, Sept. 27, 2016 – Statins are the go-to therapy for lowering "bad" LDL cholesterol, but other treatments also can effectively reduce risk of future heart problems, a new evidence review reports. These alternative therapies – including a heart-healthy diet, other cholesterol-lowering medications, and even intestinal bypass surgery – seem to confer the same level of heart health ...

Negative News on Statins Tied to Dropped Prescriptions

Posted 2 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 2, 2015 – News reports on the downsides of statins may push some people to stop taking the cholesterol-lowering drugs, a new study hints. The findings, published Dec. 2 in the European Heart Journal, cannot prove that media stories drive statin users to give up their prescriptions. Instead, Danish researchers found a broad correlation between "negative" media coverage and ...

Heart Disease Doesn't Take a Holiday

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – People with heart disease should take a number of precautions if they travel over the Thanksgiving holiday, an expert suggests. The first step is to be as well-prepared on your trip as you are at home, said Dr. Winston Gandy Jr., a cardiologist at Piedmont Heart Institute in Atlanta. "Make sure when you travel that you have your medicine," Gandy said in an American ...

FDA OKs Praluent - First of New Class of Cholesterol Drugs

Posted 27 Jul 2015 by Drugs.com

FRIDAY, July 24, 2015 – The U.S. Food and Drug Administration on Friday approved Praluent, the first of a powerful new class of injected, cholesterol-lowering drugs that experts believe could change cardiovascular care. Praluent (alirocumab) sharply cuts levels of LDL ("bad") cholesterol, and is one of a group of newly developed drugs called PCSK9 inhibitors, the FDA explained in a news release. ...

Praluent Approved to Treat High Cholesterol

Posted 27 Jul 2015 by Drugs.com

MONDAY, July 27, 2015 – Praluent (alirocumab) injection has been approved by the U.S. Food and Drug Administration to treat people with inherited high cholesterol (heterozygous familial hypercholesterolemia) or people at risk of heart attack or stroke from high cholesterol derived from foods or produced by the liver. The drug is sanctioned for people who do not benefit enough from improved diet ...

FDA Approves Praluent (alirocumab) to Treat Certain Patients with High Cholesterol

Posted 27 Jul 2015 by Drugs.com

July 24, 2015 – The U.S. Food and Drug Administration today approved Praluent (alirocumab) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial ...

Ask a Question

Further Information

Related Condition Support Groups

High Cholesterol - Familial Heterozygous, Cardiovascular Risk Reduction, High Cholesterol - Familial Homozygous, High Cholesterol

Related Drug Support Groups

Praluent

Alirocumab Patient Information at Drugs.com